Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Ocugen已完成OCU410（AAV-hRORA）在地理萎縮的第三個相1/2 ArMaDa試驗中的第三個隊列的劑量，該公司已啓動第2階段試驗以評估更大的患者群體。
Ocugen Has Completed Dosing In Third Cohort Of Phase 1/2 ArMaDa Trial For OCU410 (AAV-hRORA) For Geographic Atrophy, The Company Has Initiated Phase 2 Trial To Assess OCU410 In Larger Group Of Patients
Ocugen已完成OCU410（AAV-hRORA）在地理萎縮的第三個相1/2 ArMaDa試驗中的第三個隊列的劑量，該公司已啓動第2階段試驗以評估更大的患者群體。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。